[10-Q] Akari Therapeutics plc ADR (0.01 USD) Quarterly Earnings Report
Akari Therapeutics, Plc reported a six-month net loss of $5.6 million and a cash and restricted cash balance of $2.7 million as of June 30, 2025. The company recorded an accumulated deficit of $252.9 million and explicitly stated that its cash balance is not sufficient to fund operations for the one-year period following issuance, which management says raises substantial doubt about the Company’s ability to continue as a going concern.
In November 2024 Akari completed the acquisition of Peak Bio, recording $39.18 million of in‑process R&D (IPR&D) and $8.43 million of goodwill tied to its ADC platform and payload PH1. During H1 2025 the company completed a March 2025 private placement with net proceeds of approximately $5.6 million and recognized a $1.2 million gain from settlement of payables. Shares outstanding increased to 65.23 billion ordinary shares at June 30, 2025, reflecting multiple financings and conversions. Subsequent events disclosed an August 2025 note purchase commitment for an aggregate purchase price of $3.0 million (aggregate principal issuable $3.8 million), expected to close in tranches.
Akari Therapeutics, Plc ha registrato una perdita netta di sei mesi di $5.6 million e una disponibilità di cassa e contanti vincolati pari a $2.7 million al 30 giugno 2025. La società ha un disavanzo accumulato di $252.9 million e dichiara esplicitamente che la sua disponibilità di cassa non è sufficiente a finanziare le operazioni per il periodo di un anno successivo alla data di emissione, circostanza che la direzione ritiene metta seri dubbi sulla capacità della Società di proseguire come azienda in funzionamento.
Nel novembre 2024 Akari ha completato l'acquisizione di Peak Bio, contabilizzando $39.18 million di ricerca e sviluppo in corso (IPR&D) e $8.43 million di avviamento legato alla sua piattaforma ADC e al payload PH1. Nel primo semestre 2025 la società ha portato a termine un collocamento privato di marzo 2025 con proventi netti di circa $5.6 million e ha riconosciuto un utile di $1.2 million derivante dall'estinzione di debiti. Le azioni in circolazione sono salite a 65,23 miliardi di azioni ordinarie al 30 giugno 2025, a seguito di molteplici finanziamenti e conversioni. Tra gli eventi successivi è stato comunicato un impegno di acquisto di note nell'agosto 2025 per un prezzo d'acquisto complessivo di $3.0 million (capitale complessivo emettibile $3.8 million), che dovrebbe essere finalizzato in tranche.
Akari Therapeutics, Plc registró una pérdida neta de seis meses de $5.6 million y un saldo de efectivo y efectivo restringido de $2.7 million al 30 de junio de 2025. La compañía mostró un déficit acumulado de $252.9 million y declaró explícitamente que su saldo de efectivo no es suficiente para financiar las operaciones durante el período de un año siguiente a la emisión, lo que la dirección considera que plantea dudas sustanciales sobre la capacidad de la Compañía para continuar como negocio en funcionamiento.
En noviembre de 2024 Akari completó la adquisición de Peak Bio, registrando $39.18 million de I+D en curso (IPR&D) y $8.43 million de plusvalía asociada a su plataforma ADC y al payload PH1. Durante el primer semestre de 2025 la compañía cerró un colocación privada en marzo de 2025 con ingresos netos de aproximadamente $5.6 million y reconoció una ganancia de $1.2 million por la cancelación de cuentas por pagar. Las acciones en circulación aumentaron a 65,23 mil millones de acciones ordinarias al 30 de junio de 2025, reflejando múltiples financiaciones y conversiones. Entre los hechos posteriores se divulgó un compromiso de compra de pagarés en agosto de 2025 por un precio de compra agregado de $3.0 million (principal acumulado emitible $3.8 million), que se espera se cierre en tramos.
Akari Therapeutics, Plc는 2025년 상반기에 $5.6 million의 순손실을 보고했으며, 2025년 6월 30일 기준 현금 및 제한된 현금 잔액은 $2.7 million이라고 밝혔습니다. 회사는 $252.9 million의 누적 적자를 기록했으며, 발행일로부터 1년 기간 동안 운영을 자금 지원하기에 현금 잔액이 충분하지 않다고 명시적으로 언급했는데, 경영진은 이 점이 회사가 계속기업으로 존속할 수 있는지에 대한 중대한 의문을 제기한다고 판단하고 있습니다.
2024년 11월 Akari는 Peak Bio 인수를 완료했고, ADC 플랫폼 및 페이로드 PH1과 관련해 진행 중인 연구개발(IPR&D)로 $39.18 million을, 영업권으로 $8.43 million을 계상했습니다. 2025년 상반기에는 2025년 3월 사모주식 배정(프라이빗 플레이스먼트)을 완료해 순수익 약 $5.6 million을 확보했고, 채무 정산으로부터 $1.2 million의 이익을 인식했습니다. 유통 주식수는 2025년 6월 30일 기준 652억3천만 주(보통주)로 증가했으며, 이는 다수의 자금조달 및 전환에 따른 결과입니다. 이후 공시된 사건으로는 2025년 8월 발행 약정이 있는데 총 매입대금은 $3.0 million이며(발행 가능한 총 원금 $3.8 million), 단계적으로 마감될 예정입니다.
Akari Therapeutics, Plc a annoncé une perte nette semestrielle de $5.6 million et un solde de trésorerie et équivalents de trésorerie restreints de $2.7 million au 30 juin 2025. La société affiche un déficit accumulé de $252.9 million et a déclaré explicitement que sa trésorerie n'était pas suffisante pour financer les opérations pendant la période d'un an suivant la date d'émission, ce que la direction considère comme soulevant un doute substantiel sur la capacité de la Société à poursuivre son activité en tant qu'entreprise en continuité d'exploitation.
En novembre 2024, Akari a finalisé l'acquisition de Peak Bio, enregistrant $39.18 million de R&D en cours (IPR&D) et $8.43 million de goodwill lié à sa plateforme ADC et au payload PH1. Au premier semestre 2025, la société a réalisé un placement privé en mars 2025 avec des produits nets d'environ $5.6 million et a comptabilisé un gain de $1.2 million lié au règlement de dettes fournisseurs. Le nombre d'actions en circulation est passé à 65,23 milliards d'actions ordinaires au 30 juin 2025, reflétant plusieurs financements et conversions. Parmi les événements postérieurs figure un engagement d'achat de billets en août 2025 pour un prix d'achat total de $3.0 million (principal total émettable $3.8 million), qui devrait être réalisé en tranches.
Akari Therapeutics, Plc meldete für sechs Monate einen Nettoverslust von $5.6 million und einen Kassen- und gebundenen Kassenbestand von $2.7 million zum 30. Juni 2025. Das Unternehmen wies einen aufgelaufenen Fehlbetrag von $252.9 million aus und erklärte ausdrücklich, dass der Kassenbestand nicht ausreiche, um die Geschäftstätigkeit für den ein Jahr nach Ausgabedatum folgenden Zeitraum zu finanzieren, was das Management nach eigener Aussage erhebliche Zweifel an der Fortführungsfähigkeit des Unternehmens aufkommen lasse.
Im November 2024 schloss Akari die Übernahme von Peak Bio ab und verbuchte $39.18 million für laufende F&E (IPR&D) sowie $8.43 million Geschäfts- oder Firmenwert im Zusammenhang mit seiner ADC‑Plattform und dem Payload PH1. Im H1 2025 führte das Unternehmen eine Privatplatzierung im März 2025 mit Nettoerlösen von ca. $5.6 million durch und erkannte einen Gewinn von $1.2 million aus der Begleichung von Verbindlichkeiten. Die ausstehenden Aktien stiegen zum 30. Juni 2025 auf 65,23 Milliarden Stammaktien, was mehrere Finanzierungen und Umwandlungen widerspiegelt. Nachfolgende Ereignisse offenbarten ein Note‑Kaufverpflichtung im August 2025 mit einem aggregierten Kaufpreis von $3.0 million (ausgebbares aggregiertes Kapital $3.8 million), das voraussichtlich in Tranchen geschlossen wird.
- Peak Bio acquisition recorded with $39.18M of IPR&D and $8.43M of goodwill, adding an ADC platform and novel payload PH1.
- March 2025 private placement generated approximately $5.6M in net proceeds (net of a $1.0M note termination).
- Gain on settlement of payables of approximately $1.2M recognized during the six months ended June 30, 2025.
- August 2025 Note Purchase Agreements disclosed as subsequent events for an aggregate purchase price of $3.0M (aggregate principal issuable $3.8M), indicating additional committed financing.
- Settlement with Sabby resolved by issuance of ADSs, removing open litigation exposure related to that claim.
- Substantial doubt about going concern: cash of $2.7M is stated as insufficient to fund operations for the one-year period after issuance of these financial statements.
- Continuing losses and large accumulated deficit: net loss of $5.6M for six months and accumulated deficit of $252.9M.
- Convertible notes in default: April 2023 convertible notes principal $0.7M remained in default as of June 30, 2025.
- Significant dilution: ordinary shares issued increased from ~53.19B to 65.23B outstanding at June 30, 2025 and large outstanding warrants/options create further dilution risk.
- Material warrant liabilities and valuation volatility: liability-classified warrants totaled $0.9M at June 30, 2025 with changes in fair value affecting results.
- Operational contraction and restructuring: prior reduction-in-force (~67% workforce reduction) and suspended legacy programs indicate strategic shift and cost base uncertainty.
Insights
TL;DR: Low liquidity and continuing losses create near-term financing risk despite acquisition of valuable ADC IPR&D.
Akari recorded $2.7M in cash and a six-month net loss of $5.6M, with an accumulated deficit of $252.9M. Management explicitly states cash is insufficient to fund operations for the next year and discloses substantial doubt about going concern. On the positive side, the Peak Bio acquisition added $39.18M of IPR&D and $8.43M of goodwill, and the March 2025 financing generated ~$5.6M net proceeds. The August 2025 note agreements for a $3.0M purchase price are disclosed as subsequent events but are expected to close in tranches, so their near-term cash impact is contingent on closing.
TL;DR: Acquisition materially added IPR&D and warrants/liabilities, but financing and dilution are significant.
The November 2024 merger with Peak Bio was accounted for as a business combination allocating $39.18M to IPR&D and $8.43M to goodwill. The transaction also brought assumed warrants that were classified as liability-classified instruments and contributed to contingent liabilities. The company completed equity financings (March 2025) and disclosed an August 2025 note offering ($3.0M purchase price, $3.8M principal issuable) as a subsequent event. Share count rose to 65.23B ordinary shares and outstanding warrants and options represent substantial potential dilution.
Akari Therapeutics, Plc ha registrato una perdita netta di sei mesi di $5.6 million e una disponibilità di cassa e contanti vincolati pari a $2.7 million al 30 giugno 2025. La società ha un disavanzo accumulato di $252.9 million e dichiara esplicitamente che la sua disponibilità di cassa non è sufficiente a finanziare le operazioni per il periodo di un anno successivo alla data di emissione, circostanza che la direzione ritiene metta seri dubbi sulla capacità della Società di proseguire come azienda in funzionamento.
Nel novembre 2024 Akari ha completato l'acquisizione di Peak Bio, contabilizzando $39.18 million di ricerca e sviluppo in corso (IPR&D) e $8.43 million di avviamento legato alla sua piattaforma ADC e al payload PH1. Nel primo semestre 2025 la società ha portato a termine un collocamento privato di marzo 2025 con proventi netti di circa $5.6 million e ha riconosciuto un utile di $1.2 million derivante dall'estinzione di debiti. Le azioni in circolazione sono salite a 65,23 miliardi di azioni ordinarie al 30 giugno 2025, a seguito di molteplici finanziamenti e conversioni. Tra gli eventi successivi è stato comunicato un impegno di acquisto di note nell'agosto 2025 per un prezzo d'acquisto complessivo di $3.0 million (capitale complessivo emettibile $3.8 million), che dovrebbe essere finalizzato in tranche.
Akari Therapeutics, Plc registró una pérdida neta de seis meses de $5.6 million y un saldo de efectivo y efectivo restringido de $2.7 million al 30 de junio de 2025. La compañía mostró un déficit acumulado de $252.9 million y declaró explícitamente que su saldo de efectivo no es suficiente para financiar las operaciones durante el período de un año siguiente a la emisión, lo que la dirección considera que plantea dudas sustanciales sobre la capacidad de la Compañía para continuar como negocio en funcionamiento.
En noviembre de 2024 Akari completó la adquisición de Peak Bio, registrando $39.18 million de I+D en curso (IPR&D) y $8.43 million de plusvalía asociada a su plataforma ADC y al payload PH1. Durante el primer semestre de 2025 la compañía cerró un colocación privada en marzo de 2025 con ingresos netos de aproximadamente $5.6 million y reconoció una ganancia de $1.2 million por la cancelación de cuentas por pagar. Las acciones en circulación aumentaron a 65,23 mil millones de acciones ordinarias al 30 de junio de 2025, reflejando múltiples financiaciones y conversiones. Entre los hechos posteriores se divulgó un compromiso de compra de pagarés en agosto de 2025 por un precio de compra agregado de $3.0 million (principal acumulado emitible $3.8 million), que se espera se cierre en tramos.
Akari Therapeutics, Plc는 2025년 상반기에 $5.6 million의 순손실을 보고했으며, 2025년 6월 30일 기준 현금 및 제한된 현금 잔액은 $2.7 million이라고 밝혔습니다. 회사는 $252.9 million의 누적 적자를 기록했으며, 발행일로부터 1년 기간 동안 운영을 자금 지원하기에 현금 잔액이 충분하지 않다고 명시적으로 언급했는데, 경영진은 이 점이 회사가 계속기업으로 존속할 수 있는지에 대한 중대한 의문을 제기한다고 판단하고 있습니다.
2024년 11월 Akari는 Peak Bio 인수를 완료했고, ADC 플랫폼 및 페이로드 PH1과 관련해 진행 중인 연구개발(IPR&D)로 $39.18 million을, 영업권으로 $8.43 million을 계상했습니다. 2025년 상반기에는 2025년 3월 사모주식 배정(프라이빗 플레이스먼트)을 완료해 순수익 약 $5.6 million을 확보했고, 채무 정산으로부터 $1.2 million의 이익을 인식했습니다. 유통 주식수는 2025년 6월 30일 기준 652억3천만 주(보통주)로 증가했으며, 이는 다수의 자금조달 및 전환에 따른 결과입니다. 이후 공시된 사건으로는 2025년 8월 발행 약정이 있는데 총 매입대금은 $3.0 million이며(발행 가능한 총 원금 $3.8 million), 단계적으로 마감될 예정입니다.
Akari Therapeutics, Plc a annoncé une perte nette semestrielle de $5.6 million et un solde de trésorerie et équivalents de trésorerie restreints de $2.7 million au 30 juin 2025. La société affiche un déficit accumulé de $252.9 million et a déclaré explicitement que sa trésorerie n'était pas suffisante pour financer les opérations pendant la période d'un an suivant la date d'émission, ce que la direction considère comme soulevant un doute substantiel sur la capacité de la Société à poursuivre son activité en tant qu'entreprise en continuité d'exploitation.
En novembre 2024, Akari a finalisé l'acquisition de Peak Bio, enregistrant $39.18 million de R&D en cours (IPR&D) et $8.43 million de goodwill lié à sa plateforme ADC et au payload PH1. Au premier semestre 2025, la société a réalisé un placement privé en mars 2025 avec des produits nets d'environ $5.6 million et a comptabilisé un gain de $1.2 million lié au règlement de dettes fournisseurs. Le nombre d'actions en circulation est passé à 65,23 milliards d'actions ordinaires au 30 juin 2025, reflétant plusieurs financements et conversions. Parmi les événements postérieurs figure un engagement d'achat de billets en août 2025 pour un prix d'achat total de $3.0 million (principal total émettable $3.8 million), qui devrait être réalisé en tranches.
Akari Therapeutics, Plc meldete für sechs Monate einen Nettoverslust von $5.6 million und einen Kassen- und gebundenen Kassenbestand von $2.7 million zum 30. Juni 2025. Das Unternehmen wies einen aufgelaufenen Fehlbetrag von $252.9 million aus und erklärte ausdrücklich, dass der Kassenbestand nicht ausreiche, um die Geschäftstätigkeit für den ein Jahr nach Ausgabedatum folgenden Zeitraum zu finanzieren, was das Management nach eigener Aussage erhebliche Zweifel an der Fortführungsfähigkeit des Unternehmens aufkommen lasse.
Im November 2024 schloss Akari die Übernahme von Peak Bio ab und verbuchte $39.18 million für laufende F&E (IPR&D) sowie $8.43 million Geschäfts- oder Firmenwert im Zusammenhang mit seiner ADC‑Plattform und dem Payload PH1. Im H1 2025 führte das Unternehmen eine Privatplatzierung im März 2025 mit Nettoerlösen von ca. $5.6 million durch und erkannte einen Gewinn von $1.2 million aus der Begleichung von Verbindlichkeiten. Die ausstehenden Aktien stiegen zum 30. Juni 2025 auf 65,23 Milliarden Stammaktien, was mehrere Finanzierungen und Umwandlungen widerspiegelt. Nachfolgende Ereignisse offenbarten ein Note‑Kaufverpflichtung im August 2025 mit einem aggregierten Kaufpreis von $3.0 million (ausgebbares aggregiertes Kapital $3.8 million), das voraussichtlich in Tranchen geschlossen wird.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to ____________
Commission
File Number
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
| The
| ||||
| The
|
* Trading, but only in connection with the American Depositary Shares.
Indicate
by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| ☒ | Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO
The
number of shares of Registrant’s Ordinary Shares outstanding as of August 13, 2025 was
TABLE OF CONTENTS
| Page | ||
| PART I | FINANCIAL INFORMATION | 1 |
| Item 1. | Financial Statements (Unaudited) | 1 |
| Condensed Consolidated Balance Sheets | 1 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss | 2 | |
| Condensed Consolidated Statements of Shareholders’ Equity (Deficit) | 3 | |
| Condensed Consolidated Statements of Cash Flows | 5 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 6 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 36 |
| Item 4. | Controls and Procedures | 37 |
| PART II | OTHER INFORMATION | 38 |
| Item 1. | Legal Proceedings | 38 |
| Item 1A. | Risk Factors | 38 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 38 |
| Item 3. | Defaults Upon Senior Securities | 38 |
| Item 4. | Mine Safety Disclosures | 38 |
| Item 5. | Other Information | 38 |
| Item 6. | Exhibits | 39 |
| SIGNATURES | 40 |
| i |
GENERAL INFORMATION
Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ( “Form 10-Q”) to “Akari,” the “company,” the “Company,” “we,” “us,” “our” or similar designations refer to Akari Therapeutics, Plc and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, trade names or registered marks of their respective owners.
Statements made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of such agreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements, contracts or documents as exhibits to this Form 10-Q or to any previous filing with the Securities and Exchange Commission (“SEC”), you may read the document itself for a complete understanding of its terms.
| ii |
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact, included or incorporated in this report regarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current and future drug candidates, and the plans and objectives of management are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “intend,” “continue,” “will,” “schedule,” “would,” “aim,” “contemplate,” “estimate,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we will actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause the actual results, performance, or achievements of the Company to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements.
There are a number of important factors that could cause our actual results to differ materially from those indicated or implied by forward-looking statements. These important factors include those set forth under Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 (our “Form 10-K”) and Part II “Item 1A. Risk Factors” of this Form 10-Q and in our other disclosures and filings we have made with the SEC. These factors and the other cautionary statements made in this Form 10-Q and the documents we incorporate by reference should be read as being applicable to all related forward-looking statements whenever they appear in this Form 10-Q and the documents we incorporate by reference.
In addition, any forward-looking statements represent our estimates only as of the date that this Form 10-Q is filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. All forward-looking statements included in this Form 10-Q are made as of the date hereof and are expressly qualified in their entirety by this cautionary notice. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.
| iii |
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.
AKARI THERAPEUTICS, PLC
Condensed Consolidated Balance Sheets
(Amounts in thousands, except share and per share data)
(unaudited)
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Prepaid expenses | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Goodwill | ||||||||
| Other intangible assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Convertible notes | ||||||||
| Convertible notes, related party | — | |||||||
| Notes payable | ||||||||
| Notes payable, related party | ||||||||
| Warrant liabilities | ||||||||
| Other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Other non-current liabilities | ||||||||
| Deferred tax liability | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 13) | - | - | ||||||
| Shareholders’ equity: | ||||||||
| Share capital of $ | ||||||||
| Authorized: | ||||||||
| Additional paid-in capital | ||||||||
| Capital redemption reserve | ||||||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total shareholders’ equity | ||||||||
| Total liabilities and shareholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 1 |
AKARI THERAPEUTICS, PLC
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(amounts in thousands, except share and per share data)
(unaudited)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Merger-related costs | — | — | ||||||||||||||
| Restructuring and other costs | — | — | ||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | — | — | ||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Gain on settlement of current liabilities | — | — | ||||||||||||||
| Change in fair value of warrant liabilities | ( | ) | ||||||||||||||
| Foreign currency exchange gain (loss), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Other expense, net | — | — | — | ( | ) | |||||||||||
| Total other income (expense), net | ( | ) | ||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share –– basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted-average number of ordinary shares used in computing net loss per share –– basic and diluted | ||||||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Other comprehensive (loss) income, net of tax: | ||||||||||||||||
| Foreign currency translation adjustment | ( | ) | ( | ) | ||||||||||||
| Total other comprehensive (loss) income, net of tax | ( | ) | ( | ) | ||||||||||||
| Total comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 2 |
AKARI THERAPEUTICS, PLC
Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit)
(amounts in thousands, except share data)
(unaudited)
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | ||||||||||||||||||||||
| Six Months Ended June 30, 2025 | ||||||||||||||||||||||||||||
| Share Capital $0.0001 par value | Additional Paid-in- | Capital Redemption | Accumulated Other Comprehensive | Accumulated | Total Shareholders’ | |||||||||||||||||||||||
| Shares | Amount | Capital | Reserve | Loss | Deficit | Equity | ||||||||||||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| Issuance of share capital related to financing, net of issuance costs | — | — | — | |||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||
| Foreign currency translation | — | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| Issuance of share capital related to financing, net of issuance costs | — | — | — | |||||||||||||||||||||||||
| Issuance of share capital on conversion of convertible notes, related party | — | — | — | |||||||||||||||||||||||||
| Issuance of share capital for payments in kind | — | — | — | |||||||||||||||||||||||||
| Vesting of restricted shares | — | — | — | — | ||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||
| Foreign currency translation | — | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ||||||||||||||||||
| 3 |
| Six Months Ended June 30, 2024 | ||||||||||||||||||||||||||||
| Share Capital $0.0001 par value | Additional Paid-in- | Capital Redemption | Accumulated Other Comprehensive | Accumulated | Total Shareholders’ | |||||||||||||||||||||||
| Shares | Amount | Capital | Reserve | (Income) Loss | Deficit | Equity (Deficit) | ||||||||||||||||||||||
| Balance, December 31, 2023 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Issuance of share capital related to financing, net of issuance costs | — | — | — | |||||||||||||||||||||||||
| Vesting of restricted shares | ( | ) | — | — | — | |||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||
| Foreign currency translation | — | — | — | — | — | |||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance, March 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Balance | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Issuance of share capital related to financing, net of issuance costs | — | — | — | |||||||||||||||||||||||||
| Issuance of share capital for services | ( | ) | — | — | — | — | ||||||||||||||||||||||
| Vesting of restricted shares | ( | ) | — | — | — | — | ||||||||||||||||||||||
| Shares withheld for payroll taxes | ( | ) | ( | ) | — | — | — | — | ||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | |||||||||||||||||||||||
| Foreign currency translation | — | — | — | — | — | |||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ) | ( | ) | |||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||
| Balance | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 4 |
AKARI THERAPEUTICS, PLC
Condensed Consolidated Statements of Cash Flows
(amounts in thousands)
(unaudited)
| 2025 | 2024 | |||||||
| Six Months Ended | ||||||||
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | — | |||||||
| Stock-based compensation | ||||||||
| Issuance of share capital for payments in kind | — | |||||||
| Gain on settlement of current liabilities | ( | ) | — | |||||
| Change in fair value of warrant liabilities | ( | ) | ( | ) | ||||
| Unrealized foreign currency exchange (gains) losses | ( | ) | ||||||
| Change in assets and liabilities: | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of shares, net of issuance costs | ||||||||
| Proceeds from issuance of convertible notes | — | |||||||
| Proceeds from issuance of shares upon vesting of restricted shares | ||||||||
| Proceeds from issuance of pre-funded warrants | — | |||||||
| Repayments of notes payable | ( | ) | — | |||||
| Payments on short-term financing arrangement | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rates on cash | ( | ) | ||||||
| Net change in cash | ||||||||
| Cash and restricted cash at beginning of period | ||||||||
| Cash and restricted cash at end of period | $ | $ | ||||||
| Components of cash and restricted cash | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | — | |||||||
| Total cash and restricted cash | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: | ||||||||
| Financing costs in accounts payable | $ | $ | ||||||
| Issuance of share capital for settlement of convertible notes, related party | $ | $ | — | |||||
| Issuance of share capital for settlement of related party debt | $ | $ | — | |||||
| Issuance of share capital for payments in kind | $ | $ | — | |||||
| Seller-financed purchases | $ | $ | ||||||
| SUPPLEMENTAL CASH FLOW DISCLOSURES: | ||||||||
| Cash paid for interest | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 5 |
AKARI THERAPEUTICS, PLC
Notes to Condensed Consolidated Financial Statements
(unaudited)
Note 1. Description of Business
Business Overview
Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is developing next-generation antibody-drug conjugates, or ADCs, through its proprietary technology platform of novel payloads, enabling Akari to generate multiple ADC candidates to target a range of cancers. On March 4, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Peak Bio, Inc. (“Peak Bio”) and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”). On November 14, 2024, the Company completed the previously announced strategic business combination contemplated by the Merger Agreement (“Closing”), pursuant to which, Merger Sub merged with and into Peak Bio, with Peak Bio surviving the acquisition as a wholly owned subsidiary of Akari.
Since the Company’s acquisition of Peak Bio in November 2024, Akari has focused substantially all of its efforts on its ADC platform utilizing a novel anti-cancer payload called PH1, a spliceosome modulator. Through its payload platform, the Company aims to establish a pipeline of ADC candidates that target and directly kill cancer cells, while also activating the immune system to provide for potentially more durable and sustained efficacy and responses, thereby overcoming limitations inherent in existing ADC therapies. The Company’s activities since inception have consisted of performing research and development activities and raising capital.
The Company is subject to a number of risks similar to those of pre-clinical and clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies.
To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts, pre-clinical and regulatory activities, and clinical trials. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate its pre-clinical studies or other discovery and research activities.
Basis of presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three and six months ended June 30, 2025 are not necessarily indicative of expected results for the fiscal year ending December 31, 2025 or any other future period. The condensed balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of December 31, 2024 and notes thereto included in its Form 10-K, as filed with the SEC on April 15, 2025.
| 6 |
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of share-based awards, the valuation of warrant liabilities, the valuation of goodwill and indefinite-lived intangible assets, research and development prepayments, accruals and related expenses, and the valuation allowance for deferred income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Liquidity and Financial Condition
The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements—Going Concern, which requires management to assess the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.
The
Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $
The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in research and development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of pre-clinical research outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful.
| 7 |
Note 2. Summary of Significant Accounting Policies
The significant accounting policies and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2025. There have been no material changes in the Company’s significant accounting policies during the three and six months ended June 30, 2025.
Recent accounting pronouncements
Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first six months of 2025, no new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our accompanying unaudited consolidated financial statements.
Note 3. Agreement and Plan of Merger
In
connection with the
At the Closing, each Peak Warrant and Peak Option was converted into an Adjusted Warrant and Adjusted Option to purchase a number of Akari ordinary shares or Akari ADSs, based on the Exchange Ratio. The Adjusted Warrants and the Adjusted Options have substantially similar terms and conditions as were applicable to such Peak Warrants and Peak Options immediately prior to the Closing.
Consideration Paid
The following table summarizes the total consideration paid pursuant to the Merger Agreement, which was based on the closing market price of Akari’s ADS as of the November 14, 2024 acquisition date:
Summary of Total Consideration Paid
| ($ in thousands) | Number of ADSs issued and issuable on exercise | Consideration | ||||||
| Company ADSs issued to Peak Bio Inc. shareholders | $ | |||||||
| Company ADSs issuable on exercise of November 2022 Peak Investor Warrants and April 2023 Peak Investor Warrants | ||||||||
| Company ADSs issuable on exercise of Peak Bio Adjusted Options | — | |||||||
| Total consideration | $ | |||||||
The
fair value of the
In
connection with the acquisition of Peak Bio, the Company assumed (i) warrants issued to investors (“November 2022 Peak Warrants”)
to purchase an aggregate of
| 8 |
The Company determined that the November 2022 Peak Warrants and the April 2023 Peak Warrants are not indexed to the Company’s own stock in the manner contemplated by the relevant accounting standard. Accordingly, on the Closing of the acquisition, the Company classified these warrants as derivative liabilities in its consolidated balance sheets.
The
estimated fair value of the Adjusted Warrants of $
Summary of Assumptions Used to Determine Fair Value of the Assumed Warrants
| November 2022 | April 2023 | |||||||
| Peak Bio Assumed Warrants | ||||||||
| November 2022 | April 2023 | |||||||
| Stock (ADS) price | $ | $ | ||||||
| Exercise price | $ | $ | ||||||
| Expected term (in years) | ||||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Warrants outstanding input | % | % | ||||||
The
Company assumed Peak Bio’s outstanding stock option awards and granted options to purchase
Total Assets Acquired and Liabilities Assumed
The acquisition of Peak Bio has been accounted for as a business combination using the acquisition method of accounting. The fair value of the purchase price was allocated to the assets acquired and liabilities assumed at their respective fair values. Management estimated the fair value of the acquired in-process research and development (“IPR&D”) intangible assets using a multi-period excess earnings method. The significant assumptions used in the valuation are the probability of clinical trial success and obtaining regulatory approval, forecasted gross sales from up-front and milestone payments, royalties and product sales, and the discount rate reflecting the Company’s weighted average cost of capital. This acquisition method requires, among other things, that assets acquired, and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date.
| 9 |
The following table summarizes the final fair values of assets acquired and liabilities assumed as of the acquisition date (in thousands):
Summary of Final Fair Values of Assets Acquired and Liabilities Assumed
| Assets acquired | ||||
| Cash and restricted cash | $ | |||
| Prepaid expenses and other current assets | ||||
| Acquired in-process research and development | ||||
| Total assets acquired | ||||
| Liabilities assumed | ||||
| Accounts payable and accrued expenses | ||||
| Convertible notes | ||||
| Notes payable | ||||
| Notes payable, related party | ||||
| Deferred tax liability | ||||
| Total liabilities assumed | ||||
| Total assets acquired and liabilities assumed | ||||
| Goodwill | ||||
| Net assets acquired | $ | |||
Intangible
assets of approximately $
There were no changes to the carrying value of goodwill and other intangible assets during the three and six months ended June 30, 2025.
The fair value of IPR&D intangible assets was as follows (in thousands):
Summary of Fair Value of IPR&D Intangible Assets
| In-Process Research and Development | ||||
| AKTX-101 | $ | |||
| PHP-303 | ||||
| Total in-process research and development | $ |
The Company assumed convertible notes and notes payable with third parties, and notes payable with a related party, which are described in Note 6 and Note 12, respectively.
Pro Forma Financial Information (Unaudited)
The following table summarizes certain of the Company’s supplemental pro forma financial information for the three and six months ended June 30, 2024, as if the acquisition of Peak Bio had occurred as of January 1, 2024. The unaudited pro forma financial information for the three and six months ended June 30, 2024 reflect (i) the reversal of fair value adjustments recognized on Peak Bio’s warrant liabilities and derivative liability, and (ii) the reversal of interest and accretion expense on Peak Bio’s debt that was settled on the acquisition date. The unaudited pro-forma financial information is for comparative purposes only and is not necessarily indicative of what would have occurred had the acquisition been made at that date or of results which may occur in the future (in thousands).
Summary of Pro Forma Financial Information
| As Reported | Pro Forma | As Reported | Pro Forma | |||||||||||||
| Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | |||||||||||||||
| As Reported | Pro-Forma | As Reported | Pro-Forma | |||||||||||||
| Net loss | $ | ( | ) | ( | ) | $ | ( | ) | ( | ) | ||||||
| 10 |
Note 4. Fair Value Measurements
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:
Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis
| (In thousands) | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| June 30, 2025 | ||||||||||||||||
| (In thousands) | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liability - November 2022 Peak Warrants | $ | $ | — | $ | — | $ | ||||||||||
| Warrant liability - April 2023 Peak Warrants | — | — | ||||||||||||||
| Warrant liability - September 2022 Series B | — | — | ||||||||||||||
| Total liabilities | $ | — | — | $ | ||||||||||||
| (In thousands) | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| December 31, 2024 | ||||||||||||||||
| (In thousands) | Total | Level 1 | Level 2 | Level 3 | ||||||||||||
| Liabilities | ||||||||||||||||
| Warrant liability - November 2022 Peak Warrants | $ | $ | — | $ | — | $ | ||||||||||
| Warrant liability - April 2023 Peak Warrants | — | — | ||||||||||||||
| Warrant liability - September 2022 Series B | — | — | ||||||||||||||
| Total liabilities | $ | — | — | $ | ||||||||||||
The Company’s Level 3 liabilities consist of the September 2022 Warrants, the November 2022 Peak Warrants and the April 2023 Peak Warrants, which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the three and six months ended June 30, 2025 and the year ended December 31, 2024.
Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis
The following table summarizes the activity in the warrant liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) during the three and six months ended June 30, 2025:
Schedule of Fair value on a Recurring Basis using Unobservable Inputs
| (In thousands) | September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | Total | ||||||||||||
| Warrant Liability | ||||||||||||||||
| (In thousands) | September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | Total | ||||||||||||
| Balance, December 31, 2024 | $ | $ | $ | $ | ||||||||||||
| Change in fair value of liability | — | |||||||||||||||
| Balance, March 31, 2025 | ||||||||||||||||
| Extinguishment of liability | ( | ) | — | — | ( | ) | ||||||||||
| Change in the fair value of liability | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Balance, June 30, 2025 | $ | $ | $ | $ | ||||||||||||
The following table summarizes the activity in the warrant liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) during the three and six months ended June 30, 2024:
| (In thousands) | September 2022 Series A Warrants | September 2022 Series B Warrants | Total | |||||||||
| Warrant Liability | ||||||||||||
| (In thousands) | September 2022 Series A Warrants | September 2022 Series B Warrants | Total | |||||||||
| Balance, December 31, 2023 | $ | | $ | $ | ||||||||
| Change in fair value of liability | ( | ) | ( | ) | ( | ) | ||||||
| Balance, March 31, 2024 | — | |||||||||||
| Balance | — | |||||||||||
| Change in the fair value of liability | — | |||||||||||
| Balance, June 30, 2024 | $ | — | $ | $ | ||||||||
| Balance | $ | — | $ | $ | ||||||||
| 11 |
Assumptions Used in Determining Fair Value of Liability-Classified Warrants
The fair value of the warrant liabilities is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the liability classified warrants (each defined below) were determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Company’s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate.
Below are the assumptions used for the fair value calculations of the liability classified warrants as of June 30, 2025 and December 31, 2024:
Schedule Of Assumptions used for the Fair Value Calculations of the Warrants
| September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | |||||||||||||||||||
| June 30, 2025 | December 31, 2024 | |||||||||||||||||||||||
| September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | September 2022 Series B Warrants | November 2022 Warrants | April 2023 Warrants | |||||||||||||||||||
| Stock (ADS) price | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Exercise price | $ | $ | $ | $ | $ | $ | ||||||||||||||||||
| Expected term (in years) | ||||||||||||||||||||||||
| Expected volatility | % | % | % | % | % | % | ||||||||||||||||||
| Risk-free interest rate | % | % | % | % | % | % | ||||||||||||||||||
| Expected dividend yield | — | — | — | — | — | — | ||||||||||||||||||
| Warrant outstanding input | — | — | — | — | — | — | ||||||||||||||||||
Note 5. Accrued Expenses
Accrued expenses consisted of the following as of June 30, 2025 and December 31, 2024 (in thousands):
Summary of Accrued Expenses
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Employee compensation and benefits | $ | $ | ||||||
| External research and development expenses | ||||||||
| Professional and consulting fees | ||||||||
| Restructuring | ||||||||
| Other | ||||||||
| Total accrued expenses | $ | $ | ||||||
Note 6. Convertible Notes and Notes Payable
September 2024 Note Payable
In
November 2024, the Company assumed a promissory note issued by Peak Bio in September 2024 in the amount of $
As of June 30, 2025 and December 31, 2024, the outstanding
balance on the September 2024 Note was $
November 2023 Note Payable
In
November 2024, the Company assumed a promissory note issued by Peak Bio in November 2023 in the amount of $
| 12 |
As
of December 31, 2024, the principal balance of $
The Company did not recognize any interest expense during the three and six months ended June 30, 2025.
April 2023 Convertible Notes
In
November 2024, the Company assumed convertible promissory notes issued by Peak Bio in April 2023 in the principal amount of a total
of $
As
of June 30, 2025 and December 31, 2024, accrued interest on the April 2023 Notes of less than $
Refer to Note 12 for notes payable, related party and convertible notes, related party.
| 13 |
Note 7. Shareholders’ Equity (Deficit)
Ordinary Shares
On
June 30, 2025, the Company’s shareholders approved an increase to the number of authorized ordinary shares, par value $
Currently,
each ADS represents
March 2025 Private Placement
In
March 2025, the Company entered into a securities purchase agreement with certain investors and all directors, pursuant to which the
Company sold and issued in a private placement (the “March 2025 Private Placement”) ADSs, or pre-funded warrants
(“Pre-Funded Warrants”) in lieu thereof, each representing
In
March 2025, the Company closed its first round of financing under the March 2025 Private Placement and issued
In
April 2025, the Company closed its final round of financing under the March 2025 Private Placement and issued
At
close of the March 2025 Private Placement, the Company incurred a total of approximately $
Merger with Peak Bio, Inc.
On
November 14, 2024, the Company completed its previously announced strategic combination with Peak Bio. In connection with the acquisition,
the Company issued
The Company determined that the November 2022 Peak Warrants and the April 2023 Peak Warrants are not indexed to the Company’s own stock in the manner contemplated by the relevant accounting standard. Accordingly, on the Closing of the acquisition, the Company classified these warrants as derivative liabilities in its unaudited condensed consolidated balance sheets.
| 14 |
Warrants
In connection with various previous financing transactions, the Company has issued warrants to purchase the Company’s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement.
The following table summarizes the Company’s outstanding warrant ADSs, with each ADS representing 2,000 ordinary shares, as of June 30, 2025 and December 31, 2024:
Schedule of Summarizes the Outstanding Warrants
| Number of Warrant ADSs | Weighted- | |||||||||||||
| June 30, | December 31, | Average | ||||||||||||
| 2025 | 2024 | Exercise Price | Expiration Date | |||||||||||
| Equity-classified Warrants | ||||||||||||||
| October 2023 Pre-funded Investor Warrants | $ | None | ||||||||||||
| April 2025 Pre-funded Investor Warrants | — | $ | None | |||||||||||
| March 2025 Series A Investor Warrants | — | $ | 3/6/2026 | |||||||||||
| March 2025 Series B Investor Warrants | — | $ | 3/6/2030 | |||||||||||
| April 2025 Series A Investor Warrants | — | $ | 4/25/2026 | |||||||||||
| April 2025 Series B Investor Warrants | — | $ | 4/25/2030 | |||||||||||
| May 2024 Investor Warrants | $ | May-Jun 2027 | ||||||||||||
| March 2024 Placement Agent Warrants | $ | 3/27/2029 | ||||||||||||
| May 2024 Placement Agent Warrants | $ | 5/31/2029 | ||||||||||||
| November 2024 Investor Warrants | $ | Dec 2027-Jun 2028 | ||||||||||||
| October 2023 Placement Agent Warrants | $ | 10/6/2028 | ||||||||||||
| March 2022 Investor Warrants | $ | 3/10/2027 | ||||||||||||
| March 2022 Placement Agent Warrants | $ | 3/10/2027 | ||||||||||||
| December 2021 Investor Warrants | $ | 1/4/2027 | ||||||||||||
| December 2021 Placement Agent Warrants | $ | 12/29/2026 | ||||||||||||
| 2020 Investor Warrants | - | $ | Feb-Mar 2025 | |||||||||||
| July 2021 Placement Agent Warrants | $ | 7/7/2026 | ||||||||||||
| 2020 Placement Warrants | - | $ | Feb-Mar 2025 | |||||||||||
| Equity-classified Warrants total | ||||||||||||||
| Liability-classified Warrants | ||||||||||||||
| April 2023 Peak Bio Warrants | $ | 4/28/2028 | ||||||||||||
| September 2022 Series B Investor Warrants | $ | 9/14/2029 | ||||||||||||
| November 2022 Peak Bio Warrants | $ | 11/1/2027 | ||||||||||||
| Liability-classified Warrants total | ||||||||||||||
| Total outstanding warrants | ||||||||||||||
| 15 |
The following table summarizes the Company’s warrant ADSs activity, with each ADS representing 2,000 ordinary shares, for the six months ended June 30, 2025:
Schedule of Warrants Activity
| Number of | Weighted-Average | |||||||
| Warrant ADSs | Exercise Price per ADS | |||||||
| Outstanding at December 31, 2024 | $ | |||||||
| Issued | ||||||||
| Exercised | — | — | ||||||
| Forfeited | ( | ) | ||||||
| Expired | ( | ) | ||||||
| Outstanding at June 30, 2025 | $ | |||||||
Note 8. Stock-Based Compensation
Stock Options
The following is a summary of the Company’s stock option ADSs activity, with each ADS representing 2,000 ordinary shares, under the 2014 Equity Incentive Plan, the 2023 Equity Incentive Plan and the Peak Bio 2022 Long Term Incentive Plan for the six months ended June 30, 2025:
Schedule of Stock Option Activity
| Number of Stock Option ADSs | Weighted- Average Exercise Price per ADS | Weighted- Average Remaining Contractual Life (in years) | Aggregate Intrinsic Value | |||||||||||||
| Outstanding at December 31, 2024 | $ | $ | — | |||||||||||||
| Granted | ||||||||||||||||
| Exercised | — | — | ||||||||||||||
| Forfeited | ( | ) | ||||||||||||||
| Expired | ( | ) | ||||||||||||||
| Outstanding at June 30, 2025 (1) | $ | $ | — | |||||||||||||
| Exercisable at June 30, 2025 | $ | $ | — | |||||||||||||
| (1) |
The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s ADSs for those options that had exercise prices lower than the fair value of the Company’s ordinary shares.
The
weighted-average grant-date fair value per ADS of options granted during each of the six months ended June 30, 2025 and 2024 was $
Option Valuation
The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:
Schedule of Weighted-average Assumptions And Fair Value of Share Options Granted
| 2025 | 2024 | |||||||
| Expected volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Expected dividend yield | % | % | ||||||
| Expected term (in years) | ||||||||
| 16 |
Restricted Stock Units
The
2014 Plan provided, and the 2023 Plan provides, for the award of restricted stock units (“RSUs”). RSUs are granted to
employees that are subject to time-based vesting conditions that lapse between
The following table summarizes the Company’s RSU ADSs activity, with each ADS representing 2,000 ordinary shares, for the six months ended June 30, 2025:
Schedule of RSU activity
| Time-based Awards | ||||||||
| Number of RSU ADSs | Weighted-Average Grant Date Fair Value | |||||||
| Nonvested shares at December 31, 2024 | — | $ | — | |||||
| Granted | ||||||||
| Forfeited | — | — | ||||||
| Vested | ( | ) | ||||||
| Nonvested shares at June 30, 2025 | — | $ | — | |||||
The
fair value of time-based RSUs that vested during the six months ended June 30, 2025 and 2024 was less than $
As of June 30, 2025, there were no ordinary shares underlying vested time-based RSUs pending issuance that were included in the unaudited condensed consolidated statement of shareholders’ equity (deficit).
Performance-Based Stock Options
In
March 2025, the Company granted stock option awards exercisable to purchase
Stock-Based Compensation Expense
The Company classifies stock-based compensation expense in the statements of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Total stock-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2025 and 2024, was as follows:
Schedule of Stock-based Compensation Expense in Statements of Operations
| ($ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| ($ in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Restructuring and other costs | — | — | ||||||||||||||
| Total stock-based compensation expense | $ | $ | $ | $ | ||||||||||||
| 17 |
As
of June 30, 2025, total unrecognized compensation cost related to unvested stock options was $
Note 9. Net Loss per Share
The following potential dilutive securities, presented based on ordinary shares outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share
| 2025 | 2024 | |||||||
| As at June 30, | ||||||||
| 2025 | 2024 | |||||||
| Stock options | ||||||||
| Restricted stock units | — | |||||||
| Warrants | ||||||||
| Convertible notes | ||||||||
| Total | ||||||||
Note 10. Income Taxes
In
accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim
period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current
year-to-date (interim period) basis. For the three and six months ended June 30, 2025 and 2024, the Company recorded
Note 11. Segment Information
The
Company manages its operations as a single
The Company has assembled a portfolio of pre-clinical product candidates that aim to develop next-generation precision bifunctional ADCs for the treatment of cancer. The Company has not generated any revenue since its inception and does not expect to generate any revenue from the sale of products in the near future. The Company primarily incurs expenses in connection with the research and development of its product candidates as well as general and administrative costs consisting of salaries and related costs for personnel in executive, finance and administrative functions, as well as consulting, restructuring and merger-related expenses.
| 18 |
Schedule of Significant Segment Expense Categories
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| ADC discovery and pre-clinical development | $ | ( | ) | $ | — | $ | ( | ) | $ | — | ||||||
| nomacopan HSCT-TMA (AK901) clinical program expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Chemistry, manufacturing and control | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other external development (expense) income | ( | ) | ( | ) | ( | ) | ||||||||||
| Internal and other research and development expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| General and administrative expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Merger-related costs | — | ( | ) | — | ( | ) | ||||||||||
| Restructuring and other costs | — | ( | ) | — | ( | ) | ||||||||||
| Stock-based compensation expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other segment items (1) | ( | ) | ||||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| (1) |
Assets regularly provided to the CODM are consistent with those reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash and restricted cash. All of the Company’s tangible assets are held in the United States.
Note 12. Related Party Transactions
CEO Agreement
On
May 31, 2024, the Company and Dr. Samir Patel entered into an Interim Chief Executive Officer Agreement, effective as of May 1, 2024
(the “Interim CEO Agreement”). Pursuant to the Interim CEO Agreement, Dr. Patel served as the Company’s Interim President
and Chief Executive Officer as an independent contractor on an at-will basis. The Interim CEO Agreement could be terminated by the Company
immediately for any reason. As the sole compensation for services provided under the Interim CEO Agreement, Dr. Patel was paid $
On December 12, 2024, the Company’s board of directors approved the appointment of Dr. Samir Patel to President and Chief Executive Officer, effective December 16, 2024. There were no changes to Dr. Patel’s revised compensation under the CEO Amendment Agreement described above, following Dr. Patel’s appointment as President and Chief Executive Officer on December 16, 2024. On April 21, 2025, Dr. Patel stepped down as President and Chief Executive Officer.
During
the three months ended June 30, 2025, the Company recognized (i) $
| 19 |
During
the six months ended June 30, 2025, the Company recognized (i) less than $
Notes Payable, Related Party
Pursuant to the acquisition of Peak Bio, which closed on November 14, 2024, the Company assumed three notes payable due to Dr. Huh, the Company’s Chairman of the Board.
2021 Notes
As
a result of the acquisition of Peak Bio, the Company assumed two notes in the amount of a total of $
In
connection with the March 2025 Private Placement (Note 7), Dr. Huh’s 2021 Notes including accrued interest, and a portion of his
January 2024 Note (see below), aggregating to $
As
of June 30, 2025 and December 31, 2024, the outstanding principal and accrued interest on the 2021 Notes was $
January 2024 Note
As
a result of the acquisition of Peak Bio, the Company assumed a note in the amount of $
In
connection with the March 2025 Private Placement (Note 7), a portion of Dr. Huh’s January 2024 Note and his 2021 Notes aggregating
to $
The
Company recognized interest expense of less than $
As
of June 30, 2025 and December 31, 2024, the outstanding principal balance on the January 2024 Note was $
Convertible Notes, Related Party
On
May 10, 2024, the Company entered into unsecured convertible promissory notes (the “May 2024 Notes”) with Dr. Ray Prudo,
the Company’s Chairman at the time, and its then Interim President and Chief Executive Officer and director, Dr. Samir Patel, for
an aggregate of $
| 20 |
The
Company recognized
As
of June 30, 2025 and December 31, 2024, the outstanding principal and accrued interest, presented within accrued expenses, on the May
2024 Notes was $
The Doctors Laboratory
The
Company leases office space for its U.K. headquarters in London from The Doctors Laboratory (“TDL”), an entity with a common
director, and had incurred expenses of less than $
Other
In
November 2024, the Company assumed an amount due to an entity in which the Company’s Chairman, Dr. Hoyoung Huh, is a director.
As of June 30, 2025 and December 31, 2024, the amounts due totaled less than $
Note 13. Commitments and Contingencies
Leases
The Company currently leases office space for both our U.K. and U.S. headquarters on a short-term basis. The lease for our U.K. headquarters, located in London, expired in July 2025, unless terminated earlier with not less than three months notice. The Company leases its U.S. headquarters virtual office, located in Boston, Massachusetts, on a month-to-month basis. The Company also leases laboratory space, located in San Francisco, California, which expires in September 2025 and is cancellable anytime with 60 days’ notice. The Company is not party to any material lease agreements.
For
each of the three months ended June 30, 2025 and 2024, the Company incurred lease costs of less than $
Employee Benefit Plans
The
Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows
employees to make contributions up to a specified percentage of their compensation.
During
each of the three and six months ended June 30, 2025 and 2024, respectively, the Company charged less than $
| 21 |
Bayer Acquisition Agreement
In November 2024, the Company assumed an assignment, license, development and commercialization agreement dated March 17, 2017 with Bayer (the “Bayer Acquisition Agreement”), to acquire from Bayer all right, title and interest in and to PHP-303, including each and every invention and any priority rights relating to its patents.
Under
the Bayer Acquisition Agreement, the Company is committed to pay certain development and regulatory milestones up to an aggregate amount
of $
Either party may terminate the Bayer Acquisition Agreement upon prior written notice for the other party’s material breach that remains uncured for a specified period of time or insolvency. Bayer agreed not to assert any Bayer intellectual property rights that were included in the scope of the Bayer Acquisition Agreement against the Company.
The
Company incurred
Legal Proceedings
In
May 2025, a former employee of Peak Bio CA, Inc. subsidiary filed a claim stating that they are entitled to certain discretionary bonuses
from 2022 totaling less than $
In
December 2024, the Company received demand letters from two individuals formerly serving the Company as consultants outlining claims
relating to wrongful termination. The wrongful termination claims included claims for unpaid consulting fees, consulting fees owed due
to improper termination notice, unpaid bonuses, severance, and the accelerated vesting of outstanding restricted stock unit awards as
of the termination date. On March 3, 2025 and on May 30, 2025, the Company signed separate Settlement Agreements and Mutual Releases
with each of such former consultants. The agreements require the Company to make a payment totaling $
On
November 21, 2024, “Sabby” Volatility Warrant Master Fund Ltd. (“Sabby”) filed a lawsuit against the Company
in New York state court for alleged breach of contract. Sabby alleges that it validly exercised a warrant issued to Sabby in
September 2022 and alleges that the Company breached the warrant by not honoring Sabby’s exercise request. On May 7, 2025, the
Company and Sabby entered into a Settlement Agreement pursuant to which the Company agreed to issue
Accounts Payable Settlements
During
the six months ended June 30, 2025, the Company entered into a settlement agreement with a vendor for the settlement of outstanding payables.
This resulted in a $
On April 4, 2025, the Company issued
Note 14. Restructuring
In
May 2024, the Company implemented a reduction-in-force of approximately
| 22 |
The following table presents the restructuring reserve and activity for the six months ended June 30, 2025:
Schedule of Restructuring Reserve and Accrual Activity
| Severance and | Other | |||||||||||
| (In thousands) | Employee Benefit Costs | Restructuring Charges | Total | |||||||||
| Balance at December 31, 2024 | $ | $ | — | $ | ||||||||
| Restructuring adjustment | ( | ) | — | ( | ) | |||||||
| Cash payments | ( | ) | — | ( | ) | |||||||
| Non-cash stock-based compensation | ||||||||||||
| Balance at June 30, 2025 | $ | $ | — | $ | ||||||||
The following table presents the restructuring reserve and activity for the six months ended June 30, 2024:
| Severance and | Other | |||||||||||
| (In thousands) | Employee Benefit Costs | Restructuring Charges | Total | |||||||||
| Balance at December 31, 2023 | $ | — | $ | — | $ | — | ||||||
| Restructuring charges | ||||||||||||
| Cash payments | ( | ) | ( | ) | ( | ) | ||||||
| Non-cash stock-based compensation | ( | ) | — | ( | ) | |||||||
| Balance at June 30, 2024 | $ | $ | — | $ | ||||||||
The restructuring reserve is presented within accounts payable and accrued expenses in the Company’s condensed consolidated balance sheets for the six months ended June 30, 2025 and 2024, respectively.
Note 15. Subsequent Events
In
August 2025, the Company entered into Note Purchase Agreements with certain investors and the Company’s directors (the
“August 2025 Note Investors”), pursuant to which the Company agreed to issue unsecured promissory notes with a 20%
original issuance discount (each a “August 2025 Note” and together, the “August 2025 Notes”) in a private
placement (the “August 2025 Notes Offering”) for an aggregate purchase price of $
The
Company also agreed to pay a 5% advisory fee in cash on the total gross cash proceeds of approximately $
| 23 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with:
| ● | our unaudited condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Form 10-Q; and | |
| ● | our audited consolidated financial statements and accompanying notes included in our Form 10-K, as well as the information contained under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K. |
In addition to historical information, this discussion and analysis contains forward-looking statements that are subject to risks and uncertainties, including those discussed in the section titled “Risk Factors,” set forth in Item 1A of our Form 10-K, that could cause actual results to differ materially from historical results or anticipated results.
Overview
We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) designed around novel proprietary cancer-killing toxins (“payloads”). We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
ADCs are a class of cancer therapies that combine the precision targeting of antibodies with payload toxins that attack cancer cells. To date, innovation in the field of ADC therapies has focused primarily on the development of novel antibodies linked to existing classes of payload toxins. For example, there is a range of approved ADCs with antibodies that target the Her2, Trop2, CD19, CD22, CD30, Nectin-4, Tissue Factor, and FR alpha antibodies. However, there is a lack of diversity in the payload toxins to which those antibodies are conjugated to, as more than 90% of ADCs approved or in late-stage clinical development of which we are aware, utilize payloads from just two standard classes: (1) microtubule inhibitors or (2) DNA-damaging agents such as topoisomerase I inhibitors.
Our differentiated ADC discovery and development platform (our “ADC Platform”) enables us to generate a range of ADC product candidates that pair our novel payloads with biologically validated antibody targets prevalent in cancer tumors. We believe that our focus on the development of ADCs that utilize our novel payloads may allow us to develop ADCs with benefits that include:
| ● | more effective cancer-killing properties, or cytotoxicity; | |
| ● | activation of the immune system to generate a greater numbers of neoepitopes than currently available ADCs, leading to activation of both B-cells and T-cells in the tumor microenvironment to generate an immune response that has the potential to continue to kill cancer cells in the tumor microenvironment and throughout the body; | |
| ● | ability to be used in combination with checkpoint inhibitors to potentially deliver synergistic efficacy results (more than additive); | |
| ● | sustained duration of response of tumor regression or elimination; | |
| ● | reduced tumor resistance; and | |
| ● | improved safety and tolerability relative to ADCs that are currently available. |
Our lead product candidate is AKTX-101, a pre-clinical stage Trop2-targeting ADC that combines our novel payload PH1, a spliceosome modulator with the Trop2 antibody. Trop2 is an antigen, which is expressed differentially at higher levels in a number of solid tumor cancer types, including lung, breast, colon and urothelial, and gastric. We aim to establish AKTX-101 as a potential best-in-class Trop2-targeting ADC for the treatment of a variety of solid tumors.
| 24 |
We acquired the ADC Platform in connection with our acquisition of Peak Bio (the “Merger”). Prior to that time, we were primarily focused on advancing our former lead product candidates nomacopan and PAS-nomacopan (longer-acting nomacopan that is PASylated). Since the closing of the Merger, we have focused substantially all of our efforts on the discovery and pre-clinical development of ADCs and our ADC Platform. We have suspended further internal development of our legacy programs, nomacopan and PAS-nomacopan, and intend to seek strategic partners to advance their development externally. For our PHP-303 program, a program that Peak Bio had advanced prior to the closing of the Merger, we also intend to seek strategic partners to further its development externally.
Our activities since inception have consisted of performing research and development activities and raising capital.
We do not have any products available for commercial sale, and we have not generated any product revenue from our portfolio of product candidates or other sources. Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful development and eventual commercialization of our potential therapies, which we expect, if it ever occurs, will take a number of years. The research and development efforts require significant amounts of additional capital and adequate personnel infrastructure. There can be no assurance that our research and development activities will be successfully completed, or that our potential therapies will be commercially viable.
Recent Developments
August 2025 Financing
In August 2025, we entered into Note Purchase Agreements with certain investors and the directors of the Company (the “August 2025 Note Investors”), pursuant to which we agreed to issue unsecured promissory notes with a 20% original issuance discount (each a “August 2025 Note” and together, the “August 2025 Notes”) in a private placement (the “2025 August Notes Offering”) for an aggregate purchase price of $3 million, inclusive of the exchange Note Termination (as defined below). The aggregate principal amount of the August 2025 Notes issuable is $3.8 million. The August 2025 Notes mature one year from the date of issuance at which time the principal amount is due and payable. In connection with the 2025 August Notes Offering, the Company’s Chairman, Dr. Hoyoung Huh, agreed to purchase an August 2025 Note with a principal amount of $1,250,000 for a purchase price of $1,000,000, with the purchase price thereof to be satisfied through his agreement to cancel and extinguish $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by Peak Bio in January 2024, which was assumed by the Company (the “Note Termination”) plus cash of $162,567. Further, we agreed to amend the Series A Warrants (as defined below) previously issued in the March 2025 Private Placement to certain of the August 2025 Note Investors, at the closing of the 2025 August Notes Offering to extend expiration date from 2026 to 2030. The 2025 August Notes Offering is expected to close in two tranches in August and September 2025.
We also agreed to pay a 5% transaction fee in cash of the total gross cash proceeds of $2.2 million to Paulson Investment Company (“Paulson”) in connection with the August 2025 Notes Offering.
Appointment of New President and Chief Executive Officer
On March 14, 2025, we entered into an Executive Offer of Employment Agreement (as amended by a subsequent Chief Executive Officer Letter Agreement, dated March 18, 2025) with Mr. Abizer Gaslightwala pursuant to which Mr. Gaslightwala will serve as our President and Chief Executive Officer, effective on April 21, 2025. As compensation, Mr. Gaslightwala is paid a base salary, which includes an annual cash bonus target, and is entitled to receive share-based payment compensation based on time service and the achievement of specific performance criteria.
March 2025 Private Placement
In March 2025, the Company entered into a securities purchase agreement with certain investors and all directors, pursuant to which the Company sold and issued in a private placement (the “March 2025 Private Placement”) ADSs, or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof, each representing 2,000 of the Company’s ordinary shares (the “Shares”), and, in each case, Series A warrants to purchase ADSs (“Series A Warrants”) and Series B warrants to purchase ADSs (“Series B Warrants”), the “Warrants,” and together with the ADSs or Pre-Funded Warrants, the “Units”). The Series A Warrants and Series B Warrants have a one-year term and a five-year term from the date of issuance, respectively, and the number of ADSs issuable pursuant to the exercise of each Series A Warrant ranges from 1 ADS to 1.5 ADSs depending on the “tier” of investment made.
In March 2025, the Company closed its first round of financing under the March 2025 Private Placement and issued 2,238,031 ADSs, Series A Warrants to purchase up to 2,283,031 ADS, at a per unit price of $0.87 per ADS, and Series B Warrants to purchase up to 2,283,031 ADS, at a per unit price of $0.87 per ADS. In connection with this round of financing, the Company’s Chairman, Dr. Hoyoung Huh, agreed to purchase $1.0 million of Units, with the purchase price thereof to be satisfied through his agreement to cancel and extinguish $1.0 million of notes previously issued to him by Peak Bio in January 2024, which were assumed by the Company (the “March 2025 Note Termination”) for an equal amount of ordinary shares and warrants.
In April 2025, the Company closed its final round of financing under the March 2025 Private Placement and issued 2,704,595 ADSs, Pre-Funded Warrants to purchase up to 1,650,000 ADS at a price of $0.20 per ADS, Series A Warrants to purchase up to 6,057,405 ADS, at a per unit price of $0.87 per ADS, and Series B Warrants to purchase up to 4,354,595 ADS, at a per unit price of $0.87 per ADS.
At close of the March 2025 Private Placement, we incurred a total of approximately $0.4 million in placement agent fees with Paulson and issued 172,344 ADSs with an estimated fair value of $0.2 million. Net proceeds from the March 2025 Private Placement were approximately $5.6 million, net of the $1.0 million from the March 2025 Note Termination.
| 25 |
Pipeline Prioritization of the Merged Companies
In May 2024, we announced the completion of a joint portfolio prioritization review pursuant to which the anticipated combined entity, following completion of the proposed Merger (as defined below), will focus on Peak Bio’s ADC platform technology. As a result, our clinical stage nomacopan program in hematopoietic stem cell transplantation-associated thrombotic microangiopathy (“HSCT-TMA”) was suspended, with enrollment in our pediatric clinical study discontinued due to cost and timeline. Our pre-clinical PAS-nomacopan program in Geographic Atrophy (“GA”) has also been suspended from further internal development and we are looking for an external licensing partner to continue its further development. Following the closing of the Merger on November 14, 2024, we expanded our pipeline of assets from Peak Bio with the addition of Peak Bio’s proprietary ADC technology platform with novel payload and linker technologies, as well as the Peak Bio PHP-303 small molecule selective and reversible neutrophil elastase inhibitor. The ADC program includes a novel pre-clinical ADC candidate AKTX-101 targeting Trop-2 with Akari’s novel payload, PH1. Akari aims to develop several ADC candidates utilizing its novel PH1 payload, a spliceosome modulator, to significantly improve the outcomes for cancer patients across a range of tumors. Further, related to our PHP-303 program, we do not invest any resources to advance this program internally and instead expect to emphasize partnering/collaboration and licensing opportunities with broad potential impact on patients.
Restructuring and Reduction-in-Force
In May 2024, we implemented a reduction-in-force (the “RIF”) of approximately 67% of our total workforce, as a result of the previously announced program prioritization under which our nomacopan HSCT-TMA program was suspended. The RIF was part of an operational restructuring plan and included the elimination of certain senior management positions and was completed by the end of the second quarter of 2024. The purpose of the restructuring plan, including the RIF, was to reduce HSCT-TMA related operating costs, while supporting the execution of our long-term strategic plan. For additional information, refer to Note 14 of our unaudited condensed consolidated financial statements included in this Form 10-Q.
Merger Agreement
On November 14, 2024, we completed the previously announced business combination contemplated by the Merger Agreement with Peak Bio, pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub was merged with and into Peak Bio, with Peak Bio surviving such merger as our wholly owned subsidiary.
For additional information on the Merger, refer to our Form 10-K for the fiscal year ended December 31, 2024.
| 26 |
Results of Operations
Three and Six Months Ended June 30, 2025 and 2024
Overview
During the three months ended June 30, 2025, our loss from operations totaled $3.1 million, a 58% decrease, compared to a loss from operations of $7.4 million for the three months ended June 30, 2024. During the six months ended June 30, 2025, our loss from operations totaled $6.6 million, a 51% decrease, compared to a loss from operations of $13.4 million for the six months ended June 30, 2024. Our total operating expenses are set forth by category in the table below:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||
| June 30, | June 30, | Change | ||||||||||||||||||||||
| ($ in thousands) | 2025 | 2024 | $ Change | 2025 | 2024 | $ | ||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Research and development | $ | 667 | $ | 3,314 | $ | (2,647 | ) | $ | 1,480 | $ | 5,593 | $ | (4,113 | ) | ||||||||||
| General and administrative | 2,452 | 2,241 | 211 | 5,164 | 4,907 | 257 | ||||||||||||||||||
| Merger-related costs | — | 254 | (254 | ) | — | 1,298 | (1,298 | ) | ||||||||||||||||
| Restructuring and other costs | — | 1,640 | (1,640 | ) | — | 1,640 | (1,640 | ) | ||||||||||||||||
| Total operating expenses | $ | 3,119 | $ | 7,449 | $ | (4,330 | ) | $ | 6,644 | $ | 13,438 | $ | (6,794 | ) | ||||||||||
| Loss from operations | $ | (3,119 | ) | $ | (7,449 | ) | $ | 4,330 | $ | (6,644 | ) | $ | (13,438 | ) | $ | 6,794 | ||||||||
Research and development expenses
Our research and development expenses are charged to operations as incurred and we incur both direct and indirect expenses for each of our programs. We track direct research and development expenses by pre-clinical and clinical programs, which may include third-party costs such as costs related to Contract Research Organizations (“CROs”), contract laboratories, consulting, and clinical trial costs. We do not allocate indirect research and development expenses, which may include product development and manufacturing, clinical, medical, regulatory, laboratory (equipment and supplies), personnel, facility and other overhead costs, to specific programs.
During the three months ended June 30, 2025, total research and development expenses decreased by approximately $2.6 million, or 80%, as compared to the three months ended June 30, 2024. During the six months ended June 30, 2025, total research and development expenses decreased by approximately $4.1 million, or 74%, as compared to the six months ended June 30, 2024. The reduction in research and development expenses is due to the decrease of costs associated with our legacy assets nomacopan and PHP-303 as we suspended the internal development of those programs while we prioritize our research and development activities on our ADC platform and pipeline. The following sets forth research and development expenses for the three and six months ended June 30, 2025 and 2024 by category:
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||
| June 30, | June 30, | Change | ||||||||||||||||||||||
| ($ in thousands) | 2025 | 2024 | $ Change | 2025 | 2024 | $ | ||||||||||||||||||
| Clinical trial costs: | ||||||||||||||||||||||||
| nomacopan HSCT-TMA clinical development (AK901) | $ | 44 | $ | 450 | $ | (406 | ) | $ | 106 | $ | 1,083 | $ | (977 | ) | ||||||||||
| ADC discovery and pre-clinical development | 145 | — | 145 | 162 | — | 162 | ||||||||||||||||||
| Chemistry, manufacturing and control (“CMC”) | 20 | 2,231 | (2,211 | ) | 48 | 2,942 | (2,894 | ) | ||||||||||||||||
| Other external development expenses | (63 | ) | 290 | (353 | ) | 35 | 595 | (560 | ) | |||||||||||||||
| Personnel costs | 521 | 343 | 178 | 1,129 | 973 | 156 | ||||||||||||||||||
| Total research and development expenses | $ | 667 | $ | 3,314 | $ | (2,647 | ) | $ | 1,480 | $ | 5,593 | $ | (4,113 | ) | ||||||||||
| 27 |
HSCT-TMA clinical development (AK901)
These expenses include external expenses that we have incurred in connection with the development of nomacopan for the treatment of pediatric HSCT-TMA and primarily consist of payments to CROs and other vendors. The decrease in HSCT-TMA clinical development expenses of $0.4 million and $1 million, or 90% each, incurred during the three and six months ended June 30, 2025, respectively, as compared to the three and six months ended June 30, 2024, is primarily due to our decision to suspend the AK901 clinical program and find a collaborative partner for nomacopan program.
ADC discovery and pre-clinical development
These expenses include external expenses that we incurred in connection with the discovery and pre-clinical development of our ADC platform and program(s) and primarily consist of payments to external vendors and consultants. In December 2024, we announced our strategic prioritization of our ADC technology and programs and expect to incur material additional costs going forward related to this program as we plan to invest in additional ADC related discovery and pre-clinical development activities.
Chemistry, manufacturing and control (“CMC”)
CMC expenses historically included external expenses incurred related to the development and manufacturing of nomacopan for use in clinical trials and pre-clinical development of PAS-nomacopan. In general, such expenses primarily consist of payments to vendors for manufacturing of drug substance (including raw materials), drug product, supplies, validation, quality assurance and other manufacturing development activities. The decrease in expenses of $2.2 million and $2.9 million, or 99% and 98%, incurred during the three and six months ended June 30, 2025, respectively, as compared to the three and six months ended June 30, 2024, is primarily due to our decision to suspend our HSCT-TMA program and instead seek an external partner for further development.
Other external development expenses
These expenses include external expenses, such as payments to contract vendors, that may be related to pre-clinical development activities, discontinued programs and unallocated expenses. During the three months ended June 30, 2025, we recovered certain expenses totaling less than $0.1 million resulting in a decrease of $0.4 million in expenses as compared to the three months ended June 30, 2024. The $0.6 million, or 94%, decrease in expenses incurred during the six months ended June 30, 2025, as compared to the six months ended June 30, 2024, is related to lower costs incurred related to pre-clinical studies and other pre-clinical development work investigating PAS-nomacopan for the treatment of GA.
Personnel costs
These expenses include compensation and related costs associated with employees, independent consultants and staffing firms. Personnel costs increased by $0.2 million, or 52%, and $0.2 million, or 16%, during the three and six months ended June 30, 2025, respectively, as compared to the three and six months ended June 30, 2024. The increase is primarily due to increases in non-cash stock-based compensation expense, partially offset by lower cash-based salaries.
The extent of our future research and development expenditures will be determined based on future funding.
General and administrative expenses
During the three months ended June 30, 2025, total general and administrative costs increased by approximately $0.2 million, or 9%, as compared to the three months ended June 30, 2024, primarily due to an increase in non-cash stock-based compensation expense of $0.4 million, partially offset by a decrease of approximately $0.2 million in premiums for our directors and officers insurance.
During the six months ended June 30, 2025, total general and administrative costs increased by approximately $0.3 million, or 5%, as compared to the six months ended June 30, 2024, primarily due to an increase in non-cash stock-based compensation expense of $1 million, an increase of $0.2 million in professional fees (primarily driven from Merger related financial disclosures), partially offset by a decrease of approximately $0.5 million in cash-based salaries, a decrease of approximately $0.4 million in premiums for our directors and officers insurance.
| 28 |
Merger-related costs
Merger-related costs consist of direct expenses incurred in connection with the Merger and are comprised primarily of legal and professional fees.
Merger-related costs for the three and six months ended June 30, 2024 were $0.3 million and $1.3 million, respectively. No such costs were incurred during three and six months ended June 30, 2025.
Restructuring and other costs
Restructuring costs consist primarily of severance and related benefit costs related to workforce reductions incurred in connection with the RIF, which the Company began to implement in May 2024.
Restructuring and other costs for both of the three and six months ended June 30, 2024 were $1.6 million, including $0.3 million of non-cash share-based compensation expense. No such costs were incurred during three and six months ended June 30, 2025.
Interest income
During each of the three and six months ended June 30, 2025 and 2024, interest income was less than $0.1 million. Amounts may fluctuate from period to period due to changes in average cash balances and prevailing interest rates.
Interest expense
Interest expense primarily consists of interest incurred on the May 2024 Convertible Notes, the financing of director and officer insurance premiums and the notes assumed in the Merger, which include the April 2023 Convertible Notes, the November 2023 Note, the September 2024 Note, the 2021 Notes and the January 2024 Note. Refer to Note 6 and Note 12 of our unaudited condensed consolidated financial statements included in this Form 10-Q.
Interest expense may fluctuate from period to period due to changes in average interest-bearing loans and related interest rates.
Gain on settlement of current liabilities
During the three months ended June 30, 2025, we recognized a gain on settlement of current liabilities of $1.2 million with a former vendor.
During the six months ended June 30, 2025, we recognized a gain on settlement of current liabilities of $1.2 million which is comprised of a gain on settlement of $1.2 million with a former vendor and a less than $0.1 million gain on debt extinguishment related to a promissory note issued by Peak Bio in November 2023 and assumed by the Company in November of 2024 in the amount of $0.4 million, bearing interest at 6% per annum with a maturity date of December 31, 2024 (the “November 2023 Note”).
No such gain was recognized during the three and six months ended June 30, 2024.
Change in fair value of warrant liabilities
Change in fair value of warrant liabilities represents non-cash warrant revaluation gains or losses related to the remeasurement of our liability-classified instruments, namely our September 2022 Warrants and the warrants we assumed on November 14, 2024 in connection with our acquisition of Peak Bio (the “Peak Bio Warrants”), which are more fully described in Note 4 of our condensed consolidated financial statements included in this Form 10-Q. Due to the nature of and inputs in the model used to assess the fair value of our outstanding September 2022 Warrants and Peak Bio Warrants, it is not unusual to experience significant fluctuations during each remeasurement period. These fluctuations may be due to a variety of factors, including changes in our stock price and changes in estimated stock price volatility over the remaining life of the warrants.
| 29 |
During the three months ended June 30, 2025 and 2024, we recorded a change in the fair value of warrant liabilities, representing a non-cash revaluation gain of approximately $0.1 million and a non-cash revaluation loss of $0.2 million, respectively. Change in the fair value of warrant liabilities and resulting warrant revaluation gain for the three months ended June 30, 2025 was driven by the decrease in our stock price during the reporting period. Changes in the fair value of the warrant liability and resulting warrant revaluation loss for the three months ended June 30, 2024 was driven primarily by the increase in our stock price during the reporting period.
During the six months ended June 30, 2025 and 2024, we recorded a change in the fair value of warrant liabilities, representing a non-cash revaluation gain of approximately $0.1 million and $0.5 million, respectively. Change in the fair value of warrant liabilities and resulting warrant revaluation gain for the six months ended June 30, 2025 was driven by the decrease in our stock price during the reporting period, offset by an extinguishment of liability related to certain September 2022 Warrants. Change in the fair value of warrant liabilities and resulting warrant revaluation gain for the six months ended June 30, 2024 was driven primarily by the decrease in our stock price and the decrease in the expected term assumption during the reporting period.
Foreign currency exchange gain (loss), net
During the three months ended June 30, 2025 and 2024, we recorded a net foreign currency exchange loss of less than $0.1 million and net foreign currency gain of approximately $0.1 million, respectively. During the six months ended June 30, 2025 and 2024, we recorded a net foreign currency exchange loss of approximately $0.2 million and $0.1 million, respectively. Exchange gains and losses can fluctuate significantly from period to period due to changes in exchange rates, as well as the volume and timing of expenditures and related payments denominated in foreign currencies.
Other expense, net
Other expense was less than $0.1 million during the six months ended June 30, 2024. During the three and six months ended June 30, 2025 and the three months ended June 30, 2024, we incurred no such expense. Other expenses are not material to our results of operations.
Net loss applicable to common shareholders
As a result of the factors discussed above, our net loss applicable to common shareholders for the three months ended June 30, 2025 was $1.9 million, compared to net loss applicable to ordinary shareholders for the three months ended June 30, 2024 of $7.6 million. Our net loss applicable to common shareholders for the six months ended June 30, 2025 was $5.6 million, compared to net loss applicable to ordinary shareholders for the six months ended June 30, 2024 of $13.1 million.
| 30 |
Financial Condition, Liquidity and Capital Resources
Sources of Liquidity
Since inception, we have incurred substantial losses, and we have primarily funded our operations with proceeds from the sale of equity securities, including ordinary shares, warrants and pre-funded warrants, and convertible notes. At June 30, 2025, we had $2.7 million in cash and an accumulated deficit of $252.9 million. To date, we have not generated any revenue.
We have devoted substantially all of our efforts to research and development, including clinical trials, and we have not commercialized any products. Our research and development activities, together with our general and administrative expenses, are expected to continue to result in substantial operating losses for the foreseeable future. These losses, among other things, have had and will continue to have an adverse effect on our shareholders’ equity, total assets and working capital. Due to the numerous risks and uncertainties associated with developing drug candidates and, if approved, commercial products, we are unable to predict the extent of any future losses, whether or when any of our drug candidates will become commercially available or when we will become profitable, if at all. Our future capital requirements will depend on many factors, including:
| ● | the progress and costs of our drug discovery activities and pre-clinical studies, clinical trials and other research and development activities; | |
| ● | the costs associated with the integration activities related to the Merger; | |
| ● | the scope, prioritization and number of our clinical trials and other research and development programs; | |
| ● | the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to our product candidates; | |
| ● | the costs of the development and expansion of our operational infrastructure; | |
| ● | the costs and timing of obtaining regulatory approval for our product candidates; | |
| ● | the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; | |
| ● | the costs and timing of securing manufacturing arrangements for clinical or commercial production; | |
| ● | the costs of contracting with third parties to provide sales and marketing capabilities for us; | |
| ● | the magnitude of our general and administrative expenses; and | |
| ● | any cost that we may incur under future in- and out-licensing arrangements relating to current or future product candidates. |
Other than with respect to the August 2025 Notes Offering, we currently do not have any commitments for future external funding. We will need to raise additional funds, and we may decide to raise additional funds even before we need such funds if the conditions for raising capital are available and/or favorable. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through debt or equity financings, credit facilities or by out-licensing arrangements of our product candidates. The sale of equity or convertible debt securities may result in dilution to our existing shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also subject us to covenants that restrict our operations. We cannot be certain that additional funding, whether through grants, financings, credit facilities or out-licensing arrangements, will be available to us on acceptable terms, if at all. If sufficient funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our product candidates, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain potential products that we might otherwise seek to develop or commercialize independently.
| 31 |
August 2025 Financing
In August 2025, the Company entered into Note Purchase Agreements with certain investors and the Company’s directors (the “August 2025 Note Investors”), pursuant to which the Company agreed to issue unsecured promissory notes with a 20% original issuance discount (each a “August 2025 Note” and together, the “August 2025 Notes”) in a private placement (the “August 2025 Notes Offering”) for an aggregate purchase price of $3 million, inclusive of the exchange Note Termination (as defined below). The aggregate principal amount of the August 2025 Notes issuable is $3.8 million. The August 2025 Notes mature one year from the date of issuance at which time the principal amount is due and payable. In connection with the 2025 August Notes Offering, the Company’s Chairman, Dr. Hoyoung Huh, agreed to purchase an August 2025 Note with a principal amount of $1,250,000 for a purchase price of $1,000,000, with the purchase price thereof to be satisfied through his agreement to cancel and extinguish $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by Peak Bio in January 2024, which was assumed by the Company (the “Note Termination”) plus cash of $162,567. Further, the Company agreed to amend the Series A Warrants previously issued in the March 2025 Private Placement to certain of the August 2025 Note Investors, at the closing of the 2025 August Notes Offering to extend the expiration date from 2026 to 2030. The 2025 August Notes Offering is expected to close in two tranches in August and September 2025.
The Company also agreed to pay a 5% advisory fee in cash of the total gross cash proceeds of approximately $2.2 million to Paulson Investment Company (“Paulson”) in connection with the August 2025 Notes Offering.
March 2025 Private Placement
In March 2025, the Company entered into a securities purchase agreement (the “March 2025 Private Placement”) with certain investors and all directors, pursuant to which the Company sold and issued in a private placement ADSs, or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof, each representing 2,000 of the Company’s ordinary shares (the “Shares”), and, in each case, Series A warrants to purchase ADSs (“Series A Warrants”) and Series B warrants to purchase ADSs (“Series B Warrants”), the “Warrants,” and together with the ADSs or Pre-Funded Warrants, the “Units”). The Series A Warrants and Series B Warrants have a one-year term and a five-year term from the date of issuance, respectively, and the number of ADSs issuable pursuant to the exercise of each Series A Warrant ranges from 1 ADS to 1.5 ADSs depending on the “tier” of investment made.
In March 2025, the Company closed its first round of financing under the March 2025 Private Placement and issued 2,238,031 ADSs, Series A Warrants to purchase up to 2,283,031 ADS, at a per unit price of $0.87 per ADS, and Series B Warrants to purchase up to 2,283,031 ADS, at a per unit price of $0.87 per ADS. In connection with this round of financing, the Company’s Chairman, Dr. Hoyoung Huh, agreed to purchase $1.0 million of Units, with the purchase price thereof to be satisfied through his agreement to cancel and extinguish $1.0 million of notes previously issued to him by Peak Bio in January 2024, which were assumed by the Company (the “March 2025 Note Termination”) for an equal amount of ordinary shares and warrants.
In April 2025, the Company closed its final round of financing under the March 2025 Private Placement and issued 2,704,595 ADSs, Pre-Funded Warrants to purchase up to 1,650,000 ADS at a price of $0.20 per ADS, Series A Warrants to purchase up to 6,057,405 ADS, at a per unit price of $0.87 per ADS, and Series B Warrants to purchase up to 4,354,595 ADS, at a per unit price of $0.87 per ADS. The Company received approximately $0.3 million in advance for the Pre-funded Warrants which is reflected in other current liabilities.
At close of the March 2025 Private Placement, we incurred a total of approximately $0.4 million in placement agent fees with Paulson and issued 172,344 ADSs with an estimated fair value of $0.2 million. Net proceeds from the March 2025 Private Placement were approximately $5.6 million, net of the $1.0 million from the March 2025 Note Termination.
November 2024 Private Placement
In November 2024, we entered into a definitive purchase agreement with certain investors, Dr. Ray Prudo and Dr. Samir Patel, pursuant to which we sold and issued in a private placement an aggregate of 1,713,402 ADSs, and Series D Warrants (the “Series D Warrants”) to purchase up to 1,713,402 ADSs, at a per unit price of $2.26 for aggregate gross proceeds of $3.2 million (the “November 2024 Private Placement”). The Series D Warrants have 3-year terms ranging from December 2, 2027 to June 2, 2028 and have cashless exercise provisions in limited circumstances.
At close of the November 2024 Private Placement, we incurred a total of $204,000 in placement agent fees with Paulson. Net proceeds from the November 2024 Private Placement were approximately $2.8 million after deducting placement agent fees and other expenses. In April 2025, we issued 408,000,000 ordinary shares to Paulson in lieu of $204,000 in cash payment.
May 2024 Private Placement
In May 2024, we entered into a definitive purchase agreement with certain investors, Dr. Ray Prudo and Dr. Samir Patel, pursuant to which we sold and issued in a private placement an aggregate of 4,029,754 ADSs, and May 2024 Series C Warrants (the “Series C Warrants”) to purchase up to 4,029,754 ADS, at a per unit price of $1.885 per ADS and Series C Warrant for aggregate gross proceeds of approximately $7.6 million (the “May 2024 Private Placement”). The Series C Warrants have 3-year terms ranging from May 31, 2027 to June 21, 2027 and have cashless exercise provisions in limited circumstances. The Series C Warrants (other than those issued to Dr. Prudo and Dr. Patel) have an exercise price of $1.76 per ADS. The Series C Warrants issued to Dr. Prudo and Dr. Patel have an exercise price of $1.79 per ADS. Net proceeds from the May 2024 Private Placement were approximately $7.0 million after deducting placement agent fees and other expenses.
| 32 |
May 2024 Convertible Notes
In May 2024, we entered into unsecured convertible promissory notes (the “May 2024 Notes”) with Dr. Prudo, our Chairman at the time, and our then Interim President and Chief Executive Officer and director, Dr. Patel, for an aggregate of $1.0 million in gross proceeds. The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following our receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024. Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the acquisition, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into our ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of our ADSs on the issuance date, subject to certain restrictions.
In October 2024, Drs. Prudo and Patel each elected to convert $125,000 of principal and accrued interest into our ADSs at a conversion price of $1.59 per ADS. These ordinary shares were issued during the six months ended June 30, 2025. The remaining unconverted aggregate principal balance of the May 2024 Notes, or $750,000, was repaid in cash with proceeds from our U.K. research and development tax credit from HM Revenue and Customs.
March 2024 Private Placement
In March 2024, we entered into a definitive purchase agreement with certain existing investors, pursuant to which we sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million (the “March 2024 Private Placement”). Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses.
Funding Requirements
As of the date of this report, our existing cash, together with committed funds from the August 2025 Financing, is sufficient to fund our operations into October 2025. While we have additional funding activities in progress to fund our operations, we will need to raise additional capital to continue to fund our operations and service our obligations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern. We do not currently have any products approved for sale and do not generate any revenue from product sales. We are currently seeking and expect to continue to seek additional funding through financings of equity and/or debt securities. We may also engage in strategic research and development collaborations, pre-clinical and clinical funding arrangements, the sale or license of technology assets, and/or other strategic alternatives.
Financing may not be available to us when we need it, or on favorable or acceptable terms, or at all. We could be required to seek funds through means that may require us to relinquish rights to some of our technologies, drug candidates or drugs that we would otherwise pursue on our own. In addition, if we raise additional funds by issuing equity securities, our then existing shareholders may experience dilution. The terms of any financing may adversely affect the holdings or the rights of existing shareholders. An equity financing that involves existing shareholders may cause a concentration of ownership. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and are likely to include rights that are senior to the holders of our ordinary shares. Any additional debt or equity financing may contain terms which are not favorable to us or to our shareholders, such as liquidation and other preferences, or liens or other restrictions on our assets. As discussed in Note 11 to the consolidated financial statements included in the 2024 Form 10-K, additional equity financings may also result in cumulative changes in ownership over a three-year period in excess of 50% which would limit the amount of net operating loss and tax credit carryforwards that we may utilize in any one year.
| 33 |
If we are unable to raise additional capital when required or on acceptable terms, we may be required to:
| ● | significantly delay, scale back, or discontinue the development or commercialization of our product candidates; | |
| ● | seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future; | |
| ● | dispose of technology assets, including current product candidates, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates that we otherwise would seek to develop or commercialize ourselves; | |
| ● | pursue the sale of our company to a third party at a price that may result in a loss on investment for our shareholders; or | |
| ● | file for bankruptcy or cease operations altogether. |
Any of these events could have a material adverse effect on our business, operating results, and prospects.
We believe the key factors which will affect our ability to obtain funding are:
| ● | the receptivity of the capital markets to financings by biotechnology companies generally and companies with drug candidates and technologies similar to ours specifically; | |
| ● | the receptivity of the capital markets to any in-licensing, product acquisition or other transaction we may enter into or attempt to enter into; | |
| ● | our ability to successfully integrate operations with Peak Bio following the Merger and realize anticipated benefits of the Merger; | |
| ● | the results of our pre-clinical and clinical development activities in our drug candidates we develop on the timelines anticipated; | |
| ● | competitive and potentially competitive products and technologies and investors’ receptivity to our drug candidates we develop and the technology underlying them in light of competitive products and technologies; and | |
| ● | the cost, timing, and outcome of regulatory reviews. |
In addition, increases in expenses or delays in clinical development may adversely impact our cash position and require additional funds or cost reductions.
Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the “consolidated financial statements”) are issued. Because of these uncertainties, the accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As such, the accompanying consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary if we are unable to continue as a going concern.
| 34 |
Cash Flows
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):
| Three Months Ended | ||||||||
| June 30, | ||||||||
| (In thousands) | 2025 | 2024 | ||||||
| Net cash (used in) provided by: | ||||||||
| Net cash (used in) operating activities | $ | (5,406 | ) | $ | (8,938 | ) | ||
| Net cash provided by financing activities | 5,514 | 9,277 | ||||||
| Effect of exchange rates on cash | 4 | (7 | ) | |||||
| Net change in cash | $ | 112 | $ | 332 | ||||
Operating Activities. The net cash used in operating activities for the periods presented consists primarily of our net loss adjusted for non-cash charges and changes in components of working capital. The decrease in cash used in operating activities during the six months ended June 30, 2025, as compared to the six months ended June 30, 2024, was primarily due to a decrease in research and development costs and restructuring costs related to the program reprioritization and a decrease in merger-related costs incurred in connection with the Peak Bio acquisition.
Investment Activities. There were no investing activities during the six months ended June 30, 2025 and 2024.
Financing Activities. Net cash provided by financing activities primarily consisted of the following:
| ● | For the six months ended June 30, 2025, an aggregate of $5.9 million in net proceeds received from the March 2025 Private Placement, an aggregate of $0.3 million received in advance for pre-funded warrants issued in the March 2025 Private Placement, partially offset by $0.5 million of payments related to our promissory notes and $0.3 million of payments for our insurance premium financing; and | |
| ● | For the six months ended June 30, 2024, an aggregate of $9.8 million in net proceeds received from debt and equity financings, including (i) $1.7 million in net proceeds from the March 2024 Private Placement, (ii) $1.0 million in net proceeds from the issuance of the May 2024 Notes, and (iii) $7.1 million in net proceeds from the May 2024 Private Placement, partially offset by $0.5 million in payments related to our short-term insurance premium financing arrangement. |
Material Cash Requirements
Insurance Financing Obligations
In January 2025, we entered into a short-term financing arrangement with a third-party vendor to finance insurance premiums. The aggregate amount financed under this agreement was $0.5 million which is scheduled to be paid in monthly installments through November 2025.
Debt Obligations
In November 2024 as part of the Merger, we assumed convertible notes and notes payable with third parties, and notes payable with a related party, through the acquisition of Peak Bio Inc., as more fully described in Note 6 and Note 12, respectively, to our unaudited condensed consolidated financial statements appearing in this Form 10-Q. As of June 30, 2025, these obligations are expected to result in principal payments of approximately $1.6 million.
Other
We enter into a variety of agreements and financial commitments in the normal course of business. The terms generally provide us the option to cancel, reschedule and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. However, it is not possible to predict the amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.
| 35 |
Critical Accounting Estimates
This management’s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and judgments, including, but not limited to, those related to (i) stock-based compensation, (ii) fair value of warrants classified as liabilities, (iii) research and development prepayments, accruals and related expenses, (iv) income taxes, and (v) intangible assets impairment. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
We regard an accounting estimate or assumption underlying our financial statements as a “critical accounting estimate” if:
| ● | the nature of the estimate or assumption is material due to the level of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change; and | |
| ● | the impact of the estimates and assumptions on financial condition or operating performance is material. |
There have been no material changes to our critical accounting policies and estimates since December 31, 2024. See “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Estimates” of our Form 10-K, for a discussion of significant estimates and assumptions made by our management as part of the preparation of this management’s discussion and analysis of financial condition and results of operations and accompanying condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We
are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to
provide the information required under this item.
| 36 |
Item 4. Controls and Procedures.
As previously disclosed under “Part II - Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (our “Form 10-K”), management concluded that our internal control over financial reporting was not effective at the reasonable assurance level as of December 31, 2024, due to certain deficiencies that constituted material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
We have not yet begun to engage in the implementation of remediation efforts to address the material weaknesses, as well as other identified areas of risk. For a complete description of management’s remediation plan, see “Part II - Item 9A - Controls and Procedures” in our Form 10-K.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) as of June 30, 2025. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applied its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, and previously identified material weaknesses in internal control over financial reporting, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of June 30, 2025.
Management’s Implementation of Remediation Plan
Management, with oversight from the Audit Committee, has not yet commenced implementing changes to our internal control over financial reporting in order to remediate the control deficiencies that resulted in the material weaknesses as previously disclosed in our Form 10-K. We expect to begin our efforts during the third quarter and continue our efforts through fiscal year 2025 to remediate the material weaknesses described in our Form 10-K. We believe that the remediation steps disclosed under “Part II - Item 9A - Controls and Procedures” in our Form 10-K will allow us to address the deficient controls within our internal control environment, which will facilitate the remediation of the material weaknesses.
Given that remediation efforts described in our Form 10-K have not commenced, we will not be able to consider the material weaknesses remediated until the applicable remedial controls are designed and implemented and such controls operate for a sufficient period of time and our management has concluded, through testing, that our controls are operating effectively. We, along with our Audit Committee, will continue to monitor and evaluate the effectiveness of these remedial actions and take further actions as deemed appropriate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 37 |
PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may become involved in litigation relating to claims arising out of operations in the normal course of business, which we consider routine and incidental to our business.
Refer to Note 13 of the Notes to our condensed consolidated financial statements related to commitments and contingencies, which is incorporated herein by reference.
Item 1A. Risk Factors.
Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties discussed within “Item 1A. Risk Factors” of our Form 10-K, together with all of the other information in this Form 10-Q, including the section “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our unaudited condensed consolidated financial statements and related notes, before deciding whether to purchase any of our ADSs.
There have been no material changes to the risk factors from those previously disclosed in our Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three and six months ended June 30, 2025, we did not have any sales of unregistered securities, other than as previously disclosed by us in a Current Report on Form 8-K.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None
of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934,
August 2025 Financing
In August 2025, the Company entered into Note Purchase Agreements with certain investors and the Company’s directors (the “August 2025 Note Investors”), pursuant to which the Company agreed to issue unsecured promissory notes with a 20% original issuance discount (each a “August 2025 Note” and together, the “August 2025 Notes”) in a private placement (the “August 2025 Notes Offering”) for an aggregate purchase price of approximately $3 million, inclusive of the exchange Note Termination (as defined below). The aggregate principal amount of the August 2025 Notes issuable is approximately $3.8 million. The August 2025 Notes mature one year from the date of issuance at which time the principal amount is due and payable. In connection with the 2025 August Notes Offering, the Company’s Chairman, Dr. Hoyoung Huh, agreed to purchase an August 2025 Note with a principal amount of $1,250,000 for a purchase price of $1,000,000, with the purchase price thereof to be satisfied through his agreement to cancel and extinguish $837,433 of outstanding principal and accrued interest under a senior secured promissory note previously issued to him by Peak Bio in January 2024, which was assumed by the Company (the “Note Termination”) plus cash of $162,567. Further, the Company agreed to amend the Series A Warrants previously issued in the March 2025 Private Placement to certain of the August 2025 Note Investors, to extend the expiration date of such warrants from 2026 to 2030 (such amendment, the “Series A Warrant Extension Amendment”) at the closing of the 2025 August Notes Offering. The 2025 August Notes Offering is expected to close in two tranches in August and September 2025.
The Company also agreed to pay a 5% advisory fee in cash on the total gross cash proceeds of approximately $2.2 million to Paulson Investment Company in connection with the August 2025 Notes Offering.
The issuance of the August 2025 Notes was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.
The description of the Note Purchase Agreements, the August 2025 Notes and the Series A Warrant Extension Amendment is only a summary and is qualified in its entirety by reference to the full text of the forms of the Note Purchase Agreement, August 2025 Note and Series A Warrant Extension Amendment, which are filed as Exhibits 10.2, 10.3 and 10.4, respectively, to this Quarterly Report on Form 10-Q and incorporated by reference in this Item 5.
| 38 |
Item 6. Exhibits.
Exhibit Number |
Description | |
| 2.1 | Agreement and Plan of Merger, dated as of March 4, 2024, by and among Akari Therapeutics, Plc, Peak Bio, Inc. and Pegasus Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 to Registrant’s Current Report on Form 8-K, as filed with the SEC on March 5, 2024). | |
| 10.1 | Amendment No. 2 to the Akari Therapeutics, PLC 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Registrant’s Current Report on Form 8-K, as filed with the SEC on July 1, 2025). | |
| 10.2* | Form of August 2025 Note Purchase Agreement. | |
| 10.3* | Form of 20% Original Issue Discount Promissory Note. | |
| 10.4* | Form of Amendment No. 1 to Series A Warrant. | |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101.INS | Inline XBRL Instance Document–the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. | |
| 101.SCH | lnline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* Filed herewith.
** This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Registrant specifically incorporates it by reference.
† Indicates management contract or compensatory arrangement.
| 39 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Akari Therapeutics, Plc. | ||
| By: | ||
| Date: August 13, 2025 | /s/ Abizer Gaslightwala | |
| Abizer Gaslightwala | ||
| President and Chief Executive Officer | ||
| By: | /s/ Torsten Hombeck | |
| Date: August 13, 2025 | Torsten Hombeck, Ph.D. | |
| Chief Financial Officer | ||
| 40 |
FAQ
How much cash did Akari (AKTX) have at June 30, 2025?
What was Akari's net loss for the six months ended June 30, 2025?
What material assets did Akari acquire from Peak Bio in the merger?
Does the company disclose any going concern issues?
What financing activity occurred in 2025?
Are any convertible notes in default?
How many ordinary shares were outstanding at June 30, 2025?
